BRETEC Stock Overview
Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Bioretec Oy Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.80 |
| 52 Week High | €2.90 |
| 52 Week Low | €2.02 |
| Beta | 0 |
| 1 Month Change | 12.00% |
| 3 Month Change | 19.15% |
| 1 Year Change | 5.26% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| BRETEC | FI Medical Equipment | FI Market | |
|---|---|---|---|
| 7D | -2.4% | -2.0% | -2.0% |
| 1Y | 5.3% | -32.1% | -16.3% |
Return vs Industry: BRETEC exceeded the Finnish Medical Equipment industry which returned -30.4% over the past year.
Return vs Market: BRETEC exceeded the Finnish Market which returned -15.9% over the past year.
Price Volatility
| BRETEC volatility | |
|---|---|
| BRETEC Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FI Market | 7.4% |
| 10% least volatile stocks in FI Market | 3.1% |
Stable Share Price: BRETEC has not had significant price volatility in the past 3 months.
Volatility Over Time: BRETEC's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Finnish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Timo Lehtonen | bioretec.com |
Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide. The company offers Activa IM-Nail, a bioabsorbable option for pediatric forearm intramedullary nailing; ActivaNail, an implant that is be used in upper or lower limbs to ensure successful bone regeneration; ActivaPin, a bioabsorbable implant for upper and lower limb fractures; and ActivaScrew, an absorbable surgical implant that is used in fracture treatment, osteotomy, arthrodesis, and bone graft surgery. It also provides ActivaScrew Cannulated that offers a range of fully threaded and partially threaded cannulated screws for fixation of fractures and osteotomies; ActivaScrew Interference, a tool for multiple uses regarding bone fractures, osteotomies, arthrodesesm, and bone grafts; ActivaScrew Interference TCP, a biocomposite interference screw; and RemeOs Screw, a magnesium screw implants.
Bioretec Oy Fundamentals Summary
| BRETEC fundamental statistics | |
|---|---|
| Market cap | €56.94m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs BRETEC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRETEC income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did BRETEC perform over the long term?
See historical performance and comparison